Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy
Stopeck, Alison , Abu‐Khalaf, Maysa , Chmielowski, Bartosz , Rao, Ruta , Xie, Bin , Dudek, Arkadiusz Z. , Mina, Lida A. , O’Shaughnessy, Joyce , Mattson, Paulette, Gargano, Michele , Cox, Joanna, Osterwalder, B , Drees, Jeremy, Chan, Anissa , Qiu, Xiaohong, Ottoson, Nadine, Bose, Nandita , Uhlik, Mark, Graff, J. J., Chmielowski, Bartosz , Rao, Ruta , Dudek, Arkadiusz Z , Gargano, Michele , Osterwalder, Bruno , Borges, Virginia F. , Xie, Bin, Chisamore, Michael Jon , Harrison, Ben, Ottoson, Nadine, Iglesias, José

The Journal of Immunology | May 8, 2025 | Volume: 214 | Issue: 7 | Pages: 1529-1538

10.1093/jimmun/vkaf079 | PMID 40338159 Get It

Abstract The Phase 2 IMPRIME 1 study evaluated the combination of the pathogen-associated molecular pattern (PAMP) Imprime with the immune checkpoint inhibitor (ICI) pembrolizumab as second or later line of treatment (2 L+) for patients with metastatic triple-negative breast cancer (mTNBC). Eligible patients with mTNBC received weekly Imprime (4 mg/kg) intravenously in combination with pembrolizumab (200 mg every 3 weeks). Primary endpoints were overall response rate (ORR) and safety. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression free survival (PFS), and overall survival (OS). Exploratory endpoints included correlations between immune cell activation markers in tumor tissues and blood and response to therapy. Of the 42 evaluable patients, six had a response (one complete, five partial), with an ORR of 14.3% by RECIST v1.1. Median PFS was 2.7 months, median OS was 16.4 months, and DCR was 54.8%, with responders achieving a median DoR of 15.2 months. Therapy was generally well tolerated and resulted in an increase of immune activation markers, with higher levels of activation in peripheral blood associated with response and improved survival. The combination of Imprime and pembrolizumab was safe and demonstrated immune activation in tumor tissues and peripheral blood in patients with TNBC. Improved response rates were observed compared to historical studies of ICI monotherapy in similar patient populations. Study number (ClinicalTrials.gov trial registration): NCT02981303.
Letter to the Editor: How to count from 0 to 4 without skipping a number
Kim, W. Ray, Sripongpun, Pimsiri , Charu, Vivek , Kim, W. Ray , Mannalithara, Ajitha , Charu, Vivek

Hepatology | May 8, 2025 | Volume: 82 | Issue: 2 | Pages: E31-E32

10.1097/hep.0000000000001387 | PMID 40338142 Get It

Associations between intraplaque hemorrhage and other high-risk plaque features in atherosclerotic plaques
Nguyen, Michelle T. , Benson, John C. , Larson, Anthony S. , Brinjikji, Waleed , Nasr, Deena M. , Saba, Luca , Shahid, Adnan, Larson, Anthony , Nasr, Deena , Benson, John , Shahid, Adnan Hussain , Saba, Luca , Lanzino, Giuseppe , Savastano, Luis

The Neuroradiology Journal | May 8, 2025 | Volume: 39 | Issue: 1 | Pages: 58-63

10.1177/19714009251338634 | PMID 40338133 Get It

Background: Little is known about the association between intraplaque hemorrhage (IPH) and other features of high-risk carotid atherosclerotic plaques, such as the presence of plaque ulceration, plaque enhancement, and lipid-rich necrotic core (LRNC). This study set out to assess the relationship between IPH and other vulnerable plaque features. Materials and Methods: A retrospective review was done of 102 patients with IPH in one or both of the internal carotid arteries (ICA) on neck MRA between 1/1/2016 and 3/31/2021. IPH was defined as a ≥200% signal intensity of the adjacent sternocleidomastoid muscle on MPRAGE images. All ICA plaques were assessed for the presence or absence of IPH, plaque ulceration, plaque enhancement, and LRNC, as well as IPH volume. IPH volume was measured manually by outlining the region of interest. Results: A total of 102 patients were included, with 88 (86.3%) being male. The average age was 73.5 years (SD = 9.0). Both IPH and LRNC were more commonly seen in the left carotid artery ( p = .018 and p = .047, respectively). For right-sided ICAs, there was a significant association between IPH and LRNC ( p < .0001). Lesions without IPH were more likely to have plaque enhancement than lesions with IPH ( p = .04). For left-sided ICAs, there was also a significant association between the presence of IPH and LRNC ( p < .0001). Conclusions: There is a significant association between the presence of IPH and LRNC. An inverse relationship was found between the presence of IPH and plaque enhancement for right-sided plaques. No associations were found between IPH and plaque ulceration.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
Efficacy and Morbidity of Heparin Infusion in Salvaging Autologous Breast Reconstruction Free Flaps
Odorico, Scott K. , Mazroua, Muhammad S., Wang, Leda, Day, Serena, Harless, Christin A., Martinez‐Jorge, Jorys, Vijayasekaran, Aparna , Mazroua, Muhammad Sabry, Awadallah, Andrew , Harless, Christin, Martinez-Jorge, Jorys, Awadallah, Andrew S. , Day, Serena J.

Microsurgery | May 8, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1002/micr.70065 | PMID 40341693 Get It

ABSTRACT Background Abdominal‐based free flaps are the mainstay in autologous breast reconstruction. Their safety and consistency in outcomes are well‐documented. When flap compromise occurs, operative salvage is the gold standard. However, when—and if—to place these patients on heparin infusions is unclear. The goal of this study was to investigate abdominal‐based free flap compromise and compare outcomes with and without heparin infusion. Materials and Methods This was a single‐institution, multiple‐surgeon, retrospective chart review of patients undergoing autologous, abdominal‐based free flap breast reconstruction who experienced anastomotic compromise within a 6‐year period. Treatment and outcomes data collected include flap salvage, hematoma, seroma, surgical site infection (SSI), transfusion requirement, and length of hospital stay. Results Fifty‐one flaps had evidence of compromise. A total of 31 (60.8%) patients were placed on heparin infusions after experiencing anastomotic compromise, compared to 20 who did not receive heparin infusion. Thirty‐five patients (68.6%) underwent deep inferior epigastric perforator flaps. Twenty‐six patients (51%) experienced venous congestion, 22 patients (43.1%) experienced arterial compromise, and three (5.9%) experienced both. Twenty‐eight patients (54.9%) received tissue plasminogen activator; in the heparin infusion group, 21 patients (67.7%) received tissue plasminogen activator. The total salvage rate of compromised flaps was 94.1% (48/51). There was no significant difference between heparin infusion and standard cares in length of hospital stay, length of drains in‐place, successful salvage (93.5% vs. 95%), hematoma (19.4% vs. 15%), fat necrosis, SSI, hospital readmission (19.4% vs. 15%), and return rates to the operating room (48.4% vs. 50%). However, there was a significantly higher transfusion rate in patients receiving heparin infusion (38.7% vs. 10%). Of the 25 flaps with evidence of thrombosis, 72% were placed on heparin infusions while 28% were not; there was no significant difference in salvage rate in this sub‐group. Conclusions This review of autologous breast reconstruction free flap compromise provides evidence of similar safety profiles, with similar salvage rates, when comparing salvage with and without heparin infusion; there is a higher transfusion requirement when treating with heparin infusion.
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Zhao, Yongdong , Oliver, Melissa , Schnabel, Anja , Wang, Zhaoyi , Marino, Achille , Aguiar, Cassyanne L. , Akikusa, Jonathan , Akça, Ümmüşen Kaya , Almeida, Beverley, Appenzeller, Simone , Balay‐Dustrude, Erin , Bilginer, Yelda , Cabral, David A. , Capponi, Martina , Donaldson, Nathan , Egeli, Buğra Han , Iyer, Ramesh S. , Jansson, Annette, Kostik, Inna , Kostik, Mikhail M. , Kovalick, Leonard K., Kozu, Kátia Tomie , Lee, Tzielan , Mahmood, Kamran , Muse, Ian, Mushkin, Alexander, Nowicki, Katherine D. , Nuruzzaman, Farzana , Pham, Trang Sophia, Potts, Lauren, Ramanan, Athimalaipet V., Rogers, Nathan D. , Grim, Andrew W. , Romano, Micol , Rosenwasser, Natalie , Sato, T. Shawn , Soep, Jennifer B. , Stern, Sara , Strauß, Timmy , Taneja, A. , Theos, Alexander C. , Tucker, Lori B. , Vogel, Lisa, Yasin, Shima , Wong, Stephen C. , Bouchalová, Kateřina , Hendry, Alison M., Cain, Kevin C. , Girschick, Hermann , Hedrich, Christian M. , Laxer, Ronald M. , Ferguson, Polly J. , Naden, Raymond P., Özen, Seza , Oliver, Melissa S , Akca, Ummusen Kaya , Appenzeller, Simone , Balay-Dustrude, Erin , Basiaga, Matthew L. , Kostik, Mikhail , Lapidus, Sivia K , Marrani, Edoardo , Mosa, Doaa Mosad , Nowicki, Katherine D , Pardeo, Manuela , Potts, Lauren , Ravelli, Angelo , Tucker, Lori B , Dedeoglu, Fatma , Hedrich, Christian M , Ozen, Seza , Wu, Eveline Y. , Başaran, Özge , Fox, Emily J., Insalaco, Antonella , Lapidus, Sivia , Lenert, Aleksander , Mahmood, Kamran, Mushkin, Alexander, Onel, Karen , Pham, Trang Sophia, Ramanan, Athimalaipet Vaidyanathan , Simonini, Gabriele , Dedeoğlu, Fatma

Arthritis & Rheumatology | May 8, 2025 | Volume: 78 | Issue: 3 | Pages: 537-547

10.1002/art.43137 | PMID 40342207 Get It

Objective To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
Immunopipe: a comprehensive and flexible scRNA-seq and scTCR-seq data analysis pipeline
Wang, Panwen , Yu, Yue , Zhang, Shuwen , Kocher, Jean‐Pierre , Wang, Junwen , Asmann, Yan W. , Lin, Yi, Li, Ying , Kocher, Jean-Pierre A , Wang, Junwen , Yu, Yue, Dong, Haidong , Sun, Zhifu , Zeng, Hu , Mondello, Patrizia

NAR Genomics and Bioinformatics | May 8, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1093/nargab/lqaf063 | PMID 40391086 Get It

Abstract Single-cell sequencing technologies provide us with information at the level of individual cells. Combining single-cell RNA-seq and single-cell TCR-seq profiling enables the exploration of cell heterogeneity and T-cell receptor repertoires simultaneously. Integrating both types of data can play a crucial role in enhancing our understanding of T-cell-mediated immunity and, in turn, facilitate the advancement of immunotherapy. Here, we present immunopipe, a comprehensive and flexible pipeline to perform integrated analysis of scRNA-seq and scTCR-seq data. In addition to the command line tool, we provide a user-friendly web interface for pipeline configuration and execution monitoring, benefiting researchers without extensive programming experience. With its comprehensive functionality and ease of use, immunopipe empowers researchers to uncover valuable insights from scRNA-seq and scTCR-seq data, ultimately advancing the understanding of immune responses and immunotherapy development.
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Estaris, Jonathan, Koseki, Mako , Elias, Evelyn , Chesta, Fnu , Takaoka, Kensuke , Shao, Theresa, Nishimura, Yoshito , Horita, Nobuyuki , Fujiwara, Yu

Immunotherapy | May 8, 2025 | Volume: 17 | Issue: 6 | Pages: 437-446

10.1080/1750743x.2025.2501519 | PMID 40337868 Get It

Common Antimicrobial Treatment Considerations for Patients Receiving Comfort-Focused Care: What the Hospice Provider Should Know
Crowley, Patrick , Siegel, Leslie R. , Crowley, Patrick D , Dickinson, Drew T.

Journal of Palliative Medicine | May 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/jpm.2025.0040 | PMID 40337803 Get It

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots
Toumeh, Nadia , Jabban, Yazan, Nanaa, Ahmad , He, Rong , Viswanatha, David S., Foran, James M. , Yi, Cecilia Y. Arana , Saliba, Antoine N. , Shah, Meera , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Al‐Kali, Aref , Saliba, Antoine N. , Viswanatha, David, Arana Yi, Cecilia Y , Saliba, Antoine N , Hefazi Torghabeh, Mehrdad, Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Al-Kali, Aref , Saliba, Antoine N , Jevremović, Dragan , Yi, Cecilia Arana , Hefazi, Mehrdad , Hogan, William J.

Hematology Reports | May 8, 2025 | Volume: 17 | Issue: 3 | Pages: 26

10.3390/hematolrep17030026 | PMID 40407636 Get It

Background/Objectives: DDX41, DEAD-box RNA helicase 41 gene located on chromosome 5q25.3, is one of the most mutated genes in patients with germline predisposition to myeloid neoplasms. Germline and somatic mutations often have different locations and patterns of mutation, with some hotspots displaying diversity based on ethnicity. We aimed to explore clinical outcomes in patients with various DDX41 hot-spot mutations. Methods: This was a retrospective study of patients at Mayo Clinic with DDX41 mutation identified through Next Generation Sequencing (NGS) between 2018 and 2024. We completed unadjusted comparisons using continuous or categorical variables, and survival rates were assessed using the Kaplan–Meier method and cox regression analysis. Results: Overall survival appears to be higher in those with p.M1| when compared to p.Asp140GlyFs*2 and p.Arg525His, with comparable survival between p.Arg525His and p.Asp140GlyFs*2. Among males with p.M1| who underwent bone marrow transplant, those who underwent bone marrow transplant appeared to have lower survival rates, although not statistically significant. Our study was limited by a small sample size, therefore limiting our ability to reach significance. Conclusions: Our findings suggest potential implications for clinical outcomes based on DDX41 mutation hot-spots.